Showing 1 - 10 of 531
Introducing the concept of innovation capital we will analyse conditions under which a national industry is able to succeed in international Schumpeterian competition. Then we will discuss the significance of this concept for the economic development of the German plastics industry from the...
Persistent link: https://www.econbiz.de/10010369122
Introducing the concept of innovation capital we will analyse conditions under which a national industry is able to succeed in international Schumpeterian competition. Then we will discuss the significance of this concept for the economic development of the German plastics industry from the...
Persistent link: https://www.econbiz.de/10005558492
Introducing the concept of innovation capital we will analyse conditions under which a national industry is able to succeed in international Schumpeterian competition. Then we will discuss the significance of this concept for the economic development of the German plastics industry from the...
Persistent link: https://www.econbiz.de/10011607383
This study deals with the organization of industry-science collaboration in the case of knowledge transfer for radical innovation. Based on a contingency notion, the relation between research and development (R&D) projects’ properties and the way of collaboration is explored. By means of...
Persistent link: https://www.econbiz.de/10014132966
Die im GKV-Finanzstabilisierungsgesetz verankerten Änderungen der Rahmenbedingungen für die Erstattungsbetragsverhandlungen innovativer Arzneimittel werden als Gefahr für die zukünftige Versorgung der Patienten und für den Forschungs- und Produktionsstandort gesehen. Die neuen Leitplanken...
Persistent link: https://www.econbiz.de/10013468282
The dynamics of drug launch has been an under-researched area. Most of the studies in this field focus on developed countries, quite uniform in terms of disease profile and regulatory framework, and analyse whether stringency in regulation influences launch delay. Developing countries, in...
Persistent link: https://www.econbiz.de/10011291802
The dynamics of drug launch has been an under-researched area. Most of the studies in this field focus on developed countries, quite uniform in terms of disease profile and regulatory framework, and analyse whether stringency in regulation influences launch delay. Developing countries, in...
Persistent link: https://www.econbiz.de/10009370949
The aim of this paper is to compare the evolution of antidepressant consumption in France, Germany and the United Kingdom between 1998 and 2002. Commercial databases (IMS Health) have been used in conjunction with administrative data (PACT for the UK, GKV for Germany and Afssaps for France) to...
Persistent link: https://www.econbiz.de/10005102601
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10013069689